The US Food and Drug Administration directed manufacturers of GLP-1 receptor agonists to update product labels with information on a potential risk of non-arteritic anterior ischemic optic neuropathy, or NAION. The warning covers widely used diabetes and obesity medicines, including Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound.
NAION is a rare but serious optic-nerve condition. It can cause sudden, painless loss of vision in one eye and, in some patients, permanent impairment.
The agency did not establish that GLP-1 drugs cause NAION. However, it concluded that the available evidence supports a potential increased risk and requires the warning to appear in the ‘Warnings and Precautions’ section of prescribing labels.
The FDA reviewed 126 randomized controlled trials involving multiple GLP-1 receptor agonists. The analysis found 6.4 NAION cases per 100,000 person-years among patients treated with these medicines, compared with 3.8 cases per 100,000 person-years among those receiving a placebo or another glucose-lowering drug.
The figures indicate a higher reported rate among patients taking these medicines. The FDA has framed the finding as a potential risk rather than confirmed causation, and it continues to evaluate the safety signal.
The label change applies across the GLP-1 class. It includes injectable and oral products, not only the high-profile semaglutide and tirzepatide brands.
Patients should seek urgent eye care if they develop sudden, painless vision loss in one eye. Some people notice the change on waking.
Other warning signs include blurred vision, missing areas of vision, blind spots, tunnel vision, distorted color perception and reduced central visual acuity. These symptoms may signal reduced blood flow to the optic nerve and require prompt assessment.
Doctors advise patients not to stop a prescribed GLP-1 medicine without consulting the prescriber. The FDA’s action is intended to improve awareness and encourage early reporting, not to prompt patients to stop treatment immediately.
Also Read: Novo Nordisk Share Price Rises 5% on Wegovy’s New FDA Approval for MASH